Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 811–820 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 811
- Medicine slug
- lacosamide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 74
- Source count
- 74
- Agreement rate
- 1
- Recorded readings
13 hours
- Numeric value
- 13
- Unit
- hours
- Source records
- 74
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 74 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ed5cebe-470e-48a4-86ec-2ce79cc32688 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba337b2c-7c1f-4f7b-ba93-054f502400f3 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e969b294-48d9-42a2-a093-0ac715142460 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:325df1b7-4908-0c03-e063-6294a90ad844 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb8235b4-4cd3-6f22-e053-6294a90a545c (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The elimination half-life of the unchanged drug is approximately 13 hours and is not altered by different doses, multiple dosing or intravenous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c53d6c3-fe18-dce6-a710-cb874fbf0c59 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47ae2f1f-d135-4f4e-acc2-500c1afa7b8b (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4f2620a-2047-4b33-bb75-18702f6c55e6 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c03b90e-6985-4005-b6c5-44626d0600d7 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7197c0b6-5bb9-43b3-be1d-e7615629df9a (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07b7b3f2-16a0-4deb-883b-10522676d966 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3658b3c-f193-41a2-acc7-0bb912e27173 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a273024-c2d2-4fae-90c3-b2f38a323f24 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07356cf2-224b-40d2-b827-e10a6b42c232 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:614490ce-a62c-4222-8e4b-ce802cf63028 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:779d2381-f590-45f9-a191-f44af821f4c8 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9a0ca8c-593c-48e8-b2a7-d30d5f6e6a9b (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00203a7b-e774-45f7-ac6b-48db6d32a48a (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:419ff519-2b19-4fb9-adfa-868ba0229407 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d98ec7ed-353f-4d4f-9ccd-57ddc62edd0d (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ae87834-05d8-43c8-aaa3-78047d4a573c (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ba29442-4e8a-c2b2-e063-6294a90a1bbf (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46b98d5e-fdb6-483a-b022-8b1f0aa832c5 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:024bca92-cac5-4832-a1ff-c1b3d5994ba0 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e265fd09-8149-4423-a317-5760d34b8e9b (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d7fde23-dc3f-41e9-89cf-6a1a9eeaa7de (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:145b4fae-ce6d-43e8-a474-fcb9dff92a53 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7793da3-787b-4364-9192-7caab49066f1 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f047077c-2ac7-30d0-e053-2995a90ae429 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d999f1f-11c6-bc28-e063-6394a90a4a52 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9aa6154-5d80-4597-90c3-cec131b455d4 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:973cea8d-e516-4014-a116-c5990554a550 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae9f4f1b-574d-4c9a-80cb-189ccb232723 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d2906e3-d059-425d-b971-29423963c2af (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28a594e7-e89b-4d2c-b508-11a5f74700d3 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5b91128-f838-4e98-9684-5f477fc7af06 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6140b3f1-ff60-427c-91d7-15af99fd78f1 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45786c84-51ef-4440-bc88-2501951e4c41 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3680c0ff-7f5c-4572-b1eb-4fea96b7fbe2 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d823fbfa-8ff5-4ef8-84ce-fbe916d4e430 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:458e80da-8fc1-4715-9b4b-bc4f388f933f (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:035d85e5-8688-4390-bd55-74baa91c0e9d (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dffda6c-9e44-478f-9e02-9da3ab4c50e1 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:446f14be-5d79-26b9-e063-6294a90ae0b5 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df1d2e6a-6129-49c9-b2c1-0fdf73f38b9c (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd5ac33e-6ac5-772b-2ead-d66cbd5bd1b4 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edd20b60-6265-4c4e-a95a-aaf8103cd852 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a024081a-e131-4e88-967d-40155651a945 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75de00d8-d2e7-4025-be4e-f49299068e7e (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbd80370-3d23-41f8-8914-c6ea897c0154 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba4e2e28-7dc3-47b3-9c2c-34e0b1f39fb8 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e21389b-2f51-4975-aa21-fc5c9dd9f6dc (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f37f8b8-07d3-48c4-a0c4-7652b62a1ad9 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1- to- 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7ea3ce6-4ca7-4405-a011-48e7d71360a5 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01162e2f-967b-4596-8188-c0d9889c3814 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec1c5ddb-1143-7e6a-e053-2995a90a8382 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1- to 4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc7ed8a6-acce-48f2-9ef1-4e366c71dbbc (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61e3747a-3957-4840-81f0-313aefbd5d2b (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb29da34-89aa-405a-8fbc-2308bda37187 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e24d3c45-a559-4fca-a7be-74ce37a7066e (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e79b42c-38a3-4b2c-a196-a5a1948250e2 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16a9afd2-35a6-44a9-b1d9-ca195c8640d7 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c83d2156-4dde-4316-98f1-b3dc751f3eac (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ecb8b33e-7cbd-4f5e-9fe9-e72dff9bcb86 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2098d3a5-776e-4b52-8ade-80a3ab7b3de7 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b4536d0-5703-42b0-9f59-46a3e1b75b22 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe24b28b-ca15-4dfd-a198-53cdc2c8cb99 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4ffa3ad-1278-4772-9ef8-ed6fdaa47605 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68033c90-d9cc-4d5f-896c-9a61a0c3b529 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08ac486a-4f61-4e9e-9683-d1a66a6c2a4d (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to 4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41f02424-231d-4039-a122-df4b49dc9998 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19060029-c158-4a37-9261-cfe3b2b5b1e3 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:264c3718-67ea-4483-b036-2514c853635a (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48fcaa27-baaa-446e-a282-0c3e232cd151 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
The maximum lacosamide plasma concentrations occur approximately 1-to-4-hour post-dose after oral dosing, and elimination half-life is approximately 13 hours.
Projected row 812
- Medicine slug
- lacosamide
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 74
- Source count
- 74
- Agreement rate
- 0.986486
- Recorded readings
0.6 L/kg
- Numeric value
- 0.6
- Unit
- L/kg
- Source records
- 73
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 73 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ed5cebe-470e-48a4-86ec-2ce79cc32688 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba337b2c-7c1f-4f7b-ba93-054f502400f3 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e969b294-48d9-42a2-a093-0ac715142460 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:325df1b7-4908-0c03-e063-6294a90ad844 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c53d6c3-fe18-dce6-a710-cb874fbf0c59 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47ae2f1f-d135-4f4e-acc2-500c1afa7b8b (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4f2620a-2047-4b33-bb75-18702f6c55e6 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c03b90e-6985-4005-b6c5-44626d0600d7 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7197c0b6-5bb9-43b3-be1d-e7615629df9a (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07b7b3f2-16a0-4deb-883b-10522676d966 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3658b3c-f193-41a2-acc7-0bb912e27173 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a273024-c2d2-4fae-90c3-b2f38a323f24 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07356cf2-224b-40d2-b827-e10a6b42c232 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:614490ce-a62c-4222-8e4b-ce802cf63028 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:779d2381-f590-45f9-a191-f44af821f4c8 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9a0ca8c-593c-48e8-b2a7-d30d5f6e6a9b (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00203a7b-e774-45f7-ac6b-48db6d32a48a (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:419ff519-2b19-4fb9-adfa-868ba0229407 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water. lacosamide is less than 15% bound to plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d98ec7ed-353f-4d4f-9ccd-57ddc62edd0d (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ae87834-05d8-43c8-aaa3-78047d4a573c (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ba29442-4e8a-c2b2-e063-6294a90a1bbf (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46b98d5e-fdb6-483a-b022-8b1f0aa832c5 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:024bca92-cac5-4832-a1ff-c1b3d5994ba0 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e265fd09-8149-4423-a317-5760d34b8e9b (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d7fde23-dc3f-41e9-89cf-6a1a9eeaa7de (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:145b4fae-ce6d-43e8-a474-fcb9dff92a53 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7793da3-787b-4364-9192-7caab49066f1 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f047077c-2ac7-30d0-e053-2995a90ae429 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d999f1f-11c6-bc28-e063-6394a90a4a52 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9aa6154-5d80-4597-90c3-cec131b455d4 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:973cea8d-e516-4014-a116-c5990554a550 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae9f4f1b-574d-4c9a-80cb-189ccb232723 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d2906e3-d059-425d-b971-29423963c2af (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28a594e7-e89b-4d2c-b508-11a5f74700d3 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5b91128-f838-4e98-9684-5f477fc7af06 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6140b3f1-ff60-427c-91d7-15af99fd78f1 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45786c84-51ef-4440-bc88-2501951e4c41 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3680c0ff-7f5c-4572-b1eb-4fea96b7fbe2 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d823fbfa-8ff5-4ef8-84ce-fbe916d4e430 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:458e80da-8fc1-4715-9b4b-bc4f388f933f (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:035d85e5-8688-4390-bd55-74baa91c0e9d (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dffda6c-9e44-478f-9e02-9da3ab4c50e1 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:446f14be-5d79-26b9-e063-6294a90ae0b5 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df1d2e6a-6129-49c9-b2c1-0fdf73f38b9c (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd5ac33e-6ac5-772b-2ead-d66cbd5bd1b4 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edd20b60-6265-4c4e-a95a-aaf8103cd852 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a024081a-e131-4e88-967d-40155651a945 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75de00d8-d2e7-4025-be4e-f49299068e7e (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbd80370-3d23-41f8-8914-c6ea897c0154 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba4e2e28-7dc3-47b3-9c2c-34e0b1f39fb8 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e21389b-2f51-4975-aa21-fc5c9dd9f6dc (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f37f8b8-07d3-48c4-a0c4-7652b62a1ad9 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7ea3ce6-4ca7-4405-a011-48e7d71360a5 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01162e2f-967b-4596-8188-c0d9889c3814 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec1c5ddb-1143-7e6a-e053-2995a90a8382 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc7ed8a6-acce-48f2-9ef1-4e366c71dbbc (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61e3747a-3957-4840-81f0-313aefbd5d2b (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb29da34-89aa-405a-8fbc-2308bda37187 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e24d3c45-a559-4fca-a7be-74ce37a7066e (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e79b42c-38a3-4b2c-a196-a5a1948250e2 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16a9afd2-35a6-44a9-b1d9-ca195c8640d7 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c83d2156-4dde-4316-98f1-b3dc751f3eac (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ecb8b33e-7cbd-4f5e-9fe9-e72dff9bcb86 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2098d3a5-776e-4b52-8ade-80a3ab7b3de7 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b4536d0-5703-42b0-9f59-46a3e1b75b22 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe24b28b-ca15-4dfd-a198-53cdc2c8cb99 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4ffa3ad-1278-4772-9ef8-ed6fdaa47605 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68033c90-d9cc-4d5f-896c-9a61a0c3b529 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08ac486a-4f61-4e9e-9683-d1a66a6c2a4d (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41f02424-231d-4039-a122-df4b49dc9998 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19060029-c158-4a37-9261-cfe3b2b5b1e3 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:264c3718-67ea-4483-b036-2514c853635a (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48fcaa27-baaa-446e-a282-0c3e232cd151 (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.
0.67 L/kg
- Numeric value
- 0.67
- Unit
- L/kg
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb8235b4-4cd3-6f22-e053-6294a90a545c (opens source in a new tab)
Lacosamide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is approximately 0.67 L/kg, which is close to the volume of total body water.
Projected row 813
- Medicine slug
- lamivudine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 20
- Source count
- 20
- Agreement rate
- 1
- Recorded readings
86%
- Numeric value
- 86
- Unit
- %
- Source records
- 20
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 20 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fd4d6b9-65ea-4988-8d6f-dd220ec5052d (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac824c7e-9c9f-487b-ad2f-d50eaef5cbda (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability: Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bd6b9da-df69-46db-813e-4e7f3bdecf95 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the 10-mg-per mL oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ad3a998-8e4d-43a0-8930-8f7a6ae539b4 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1be30bcc-2d9f-4afc-8f09-adc840b3f2d9 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability: Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49d53e74-3798-4463-b817-1c8beb755034 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability: Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d7db3b2-9b3c-3031-e063-6294a90a342c (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability: Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34c02bcc-d6ff-99d4-8e6a-4a91908adca8 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba7ee31e-e8d4-4e17-b27a-d2ce69e3bb00 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability: Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150 mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3637209-303e-4232-ae79-07315a990973 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef9977cb-ec91-46d7-b769-d26decfd6fe7 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability: Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e90671c6-7fff-48f4-8898-29f02d049c8b (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the 10-mg-per mL oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8a492ab-396a-4b7c-99b3-bcb6d3386f71 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability: Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150 mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87095352-c088-74b1-7be0-d3e293a90611 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the 10-mg per mL oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c30216d-f9f5-104b-e063-6294a90af8fd (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the 10-mg per mL oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89226149-47fa-4f7d-bb1f-1aa7034486b8 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability: Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bed2e227-8d36-40ea-bbbf-d8793bfda425 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability: Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150 mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47f8be59-178c-4bad-96a4-a5c82784f308 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability: Following oral administration, lamivudine is rapidly absorbed and extensively distributed.Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff3b5265-f533-4332-a861-d8c9c1664ffd (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability: Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b23aea53-324b-4ff2-8736-639e4045e388 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Absorption and Bioavailability: Absolute bioavailability in 12 adult subjects was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution.
Projected row 814
- Medicine slug
- lamivudine
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 20
- Source count
- 20
- Agreement rate
- 0.85
- Recorded readings
5 to 7 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fd4d6b9-65ea-4988-8d6f-dd220ec5052d (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t½) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac824c7e-9c9f-487b-ad2f-d50eaef5cbda (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t ½ ) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ad3a998-8e4d-43a0-8930-8f7a6ae539b4 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t½) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1be30bcc-2d9f-4afc-8f09-adc840b3f2d9 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t ½ ) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49d53e74-3798-4463-b817-1c8beb755034 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t 1/2 ) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d7db3b2-9b3c-3031-e063-6294a90a342c (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t ½ ) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34c02bcc-d6ff-99d4-8e6a-4a91908adca8 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t½) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba7ee31e-e8d4-4e17-b27a-d2ce69e3bb00 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t ½ ) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3637209-303e-4232-ae79-07315a990973 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t½) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef9977cb-ec91-46d7-b769-d26decfd6fe7 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t 1/2 ) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e90671c6-7fff-48f4-8898-29f02d049c8b (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t 1/2 ) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8a492ab-396a-4b7c-99b3-bcb6d3386f71 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t ½ ) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89226149-47fa-4f7d-bb1f-1aa7034486b8 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1–infected subjects, HBV‑infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t½) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bed2e227-8d36-40ea-bbbf-d8793bfda425 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t ½ ) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47f8be59-178c-4bad-96a4-a5c82784f308 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose studies in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t ½ ) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff3b5265-f533-4332-a861-d8c9c1664ffd (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t ½ ) ranged from 5 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b23aea53-324b-4ff2-8736-639e4045e388 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t 1/2 ) ranged from 5 to 7 hours.
13 to 19 hours
- Numeric value
- 13
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bd6b9da-df69-46db-813e-4e7f3bdecf95 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials with plasma sampling for up to 48 or 72 hours after dosing, the observed mean elimination half-life (t½) ranged from 13 to 19 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87095352-c088-74b1-7be0-d3e293a90611 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials with plasma sampling for up to 48 or 72 hours after dosing, the observed mean elimination half-life (t½) ranged from 13 to 19 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c30216d-f9f5-104b-e063-6294a90af8fd (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
In most single-dose trials with plasma sampling for up to 48 or 72 hours after dosing, the observed mean elimination half-life (t½) ranged from 13 to 19 hours.
Projected row 815
- Medicine slug
- lamivudine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 20
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
0.5 to 1 hour
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bd6b9da-df69-46db-813e-4e7f3bdecf95 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Lamivudine T max was 0.5 to 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e90671c6-7fff-48f4-8898-29f02d049c8b (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Lamivudine T max was 0.5 to 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87095352-c088-74b1-7be0-d3e293a90611 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Lamivudine T max was 0.5 to 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c30216d-f9f5-104b-e063-6294a90af8fd (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Lamivudine T max was 0.5 to 1 hour.
Projected row 816
- Medicine slug
- lamivudine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 20
- Source count
- 16
- Agreement rate
- 1
- Recorded readings
1.3 ± 0.4 L
- Numeric value
- 1.3
- Unit
- L
- Source records
- 16
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 16 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fd4d6b9-65ea-4988-8d6f-dd220ec5052d (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac824c7e-9c9f-487b-ad2f-d50eaef5cbda (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution : The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ad3a998-8e4d-43a0-8930-8f7a6ae539b4 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1be30bcc-2d9f-4afc-8f09-adc840b3f2d9 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49d53e74-3798-4463-b817-1c8beb755034 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d7db3b2-9b3c-3031-e063-6294a90a342c (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution : The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34c02bcc-d6ff-99d4-8e6a-4a91908adca8 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba7ee31e-e8d4-4e17-b27a-d2ce69e3bb00 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3637209-303e-4232-ae79-07315a990973 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef9977cb-ec91-46d7-b769-d26decfd6fe7 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8a492ab-396a-4b7c-99b3-bcb6d3386f71 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89226149-47fa-4f7d-bb1f-1aa7034486b8 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bed2e227-8d36-40ea-bbbf-d8793bfda425 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47f8be59-178c-4bad-96a4-a5c82784f308 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff3b5265-f533-4332-a861-d8c9c1664ffd (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b23aea53-324b-4ff2-8736-639e4045e388 (opens source in a new tab)
Lamivudine label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 ± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces.
Projected row 817
- Medicine slug
- lamotrigine
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 102
- Source count
- 102
- Agreement rate
- 0.843137
- Recorded readings
98%
- Numeric value
- 98
- Unit
- %
- Source records
- 86
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 86 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de700ac1-4048-467e-abb1-238953261a97 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
gine 17 2.0 (0.75-5.93) 12.6 (7.5-23.1) 1.21 (0.66-1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1a0da17-d67c-e44f-bd42-33c4009e4cdd (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf03f130-067f-401c-8501-0d78a989a319 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bbc140c-6092-416d-865d-49b89c5ecdd0 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dfdcc2d-b7c5-7abf-e063-6394a90a24a6 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e1e4fa8-881c-4618-88f6-018ab15db44d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47fd2592-2fc6-9787-e063-6394a90a8f01 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
ine 17 2.0 (0.75-5.93) 12.6 (7.5-23.1) 1.21 (0.66-1.82) Absorption: Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e5c2d76-47a6-4a57-b23c-2398b307380c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12e0be85-0961-4fe0-b973-83251ecf0f65 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20e156df-a2b6-4710-b526-0419cd17dd33 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f41c7e-03a6-b84c-e063-6294a90a7d82 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1691a60-ff0a-4755-b445-1d78309d5af0 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e243e803-e95f-47a6-a6da-5fed657f4462 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:811188be-d231-4b58-8d7a-b01b236fab51 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:812bc0d8-bb31-4fb1-9f4a-f8c17cbc769c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44670496-41ea-36a1-c435-32e359766a74 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83297e2e-9199-4b3d-9f44-a921787758fe (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
.0 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f31e1854-6068-4e45-b1e5-6def862fc466 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
.6 (7.5 to 23.1) 1.10 (0.51 to 2.22) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68a4dac2-5015-40c5-88ca-204098c3b288 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
ine 17 2.0 (0.75-5.93) 12.6 (7.5-23.1) 1.21 (0.66-1.82) Absorption: Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ef17301-6c0b-4941-a84d-12243875d2e2 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52273d60-3f27-4846-bf40-014ebcf09417 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:474fb321-575c-4b97-9dbe-080061652ee4 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:346f8af3-b850-48e4-bd6e-82ecafca86d2 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35aa48a2-2ce6-4a6e-bf5a-1bc6111d1234 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f7e59d2-4311-42a0-93a0-b29b0417d96f (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e6cc1ad-55cd-4c7f-878c-fa6716e95897 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
.6 (7.5 to 23.1) 1.10 (0.51 to 2.22) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dfb5f87-0150-4c26-a89f-34f1ab389500 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
-30.4) 12.6 (7.5-23.1) 1.10 (0.51-2.22) 1.21 (0.66-1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7587283-781b-e111-e053-6394a90ad4cc (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
.6 (7.5 to 23.1) 1.10 (0.51 to 2.22) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f54690b3-bcbb-4d94-95b9-b7591af00117 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
.6 (7.5 to 23.1) 1.10 (0.51 to 2.22) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:003663e5-c0c7-4fc1-a64d-313f2a5b10d2 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:022b0913-f683-4af8-a862-f81b315909b2 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15d801a0-f0a5-40c1-bc88-d5ba9a02c696 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e08920c2-04a3-4fb5-acc5-0af3140f82e9 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
.6 (7.5 to 23.1) 1.10 (0.51 to 2.22) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b94ae2e4-e276-40c1-bc25-da980194fc99 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
ine 17 2.0 (0.75-5.93) 12.6 (7.5-23.1) 1.21 (0.66-1.82) Absorption: Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03fd8413-df56-50ab-e063-6394a90a6950 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50fcf452-2d21-493e-a1dd-0c6ea9ac6184 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df34faa4-829e-413a-a230-cbec604eead9 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03610cdf-7eaa-445c-a441-ff17be5a7c68 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7977c87f-b459-486a-9edc-0a2071c46f4c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22225cc4-028e-43ad-8e1f-dcebdc244ecb (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60958229-5b5f-49e2-97f4-a8722138f7ce (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54ea1ec3-876b-4d3a-a92b-1a6d70951de0 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
gine 17 2.0 (0.75-5.93) 12.6 (7.5-23.1) 1.21 (0.66-1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b829f9b2-f0ac-408a-a6f4-18b72150227d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
ine 17 2.0 (0.75-5.93) 12.6 (7.5-23.1) 1.21 (0.66-1.82) Absorption: Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05cba628-b12c-44d8-89a8-3522fe417cc1 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70cd448a-2921-4c69-bdf2-5a6ce883bd07 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d33c4293-347c-49a1-9d98-f291c3dab6da (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
gine 17 2.0 (0.75-5.93) 12.6 (7.5-23.1) 1.21 (0.66-1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53774022-ea0c-42a9-a720-dc755c77b851 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09a0d30d-9b8f-4c76-8cdb-8492386b2254 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67cf961e-02b9-4a99-944f-43a55df6a544 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
gine 17 2.0 (0.75-5.93) 12.6 (7.5-23.1) 1.21 (0.66-1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b72ea7a-a0b0-4980-84ad-84f64e2e6368 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5761818-4eaf-4335-a77a-9cd703278ded (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50d46278-636a-470e-afcc-d3c8bd844e46 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
.6 (7.5 to 23.1) 1.10 (0.51 to 2.22) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ccb33cd0-e5f7-4a50-8b55-ad7c432cdb77 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcdb94a8-33be-6375-98ef-6933999d157f (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
gine 17 2.0 (0.75-5.93) 12.6 (7.5-23.1) 1.21 (0.66-1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ca9d713-ab63-48bf-9386-29301a842e60 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a9575bb-230e-46ae-b58e-41554bad45eb (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16323699-9bf8-43c7-b3aa-589156377872 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57f04b9b-06cd-8044-e063-6394a90ae733 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
.0 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7e3572d-56fe-4727-2bb4-013ccca22678 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
CTAL 17 2.0 (0.75-5.93) 12.6 (7.5-23.1) 1.21 (0.66-1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ac9dc83-edb2-4ae5-8064-40f113fd3aab (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:065e97c9-3c5f-16e6-e063-6294a90a13fc (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84277e2c-370c-4510-92bc-ef33a4a0f508 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc6e6735-d49a-44d8-936d-7c33437bc59e (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6034a8b8-9e80-43ca-b84f-ea82f788268c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ad18b68-ba16-4810-9c3e-27fa970454e8 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1601109-5c17-4482-9257-1e0be7546e8f (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ed4590d-71e3-4208-b6c0-98330acc7b85 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b5646a9-4724-44b8-8cd0-9c14f5e87f86 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a835b697-2beb-1ba8-e053-2995a90a470c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bbbe2a2-a9e8-8c13-e063-6394a90a9627 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
.6 (7.5 to 23.1) 1.10 (0.51 to 2.22) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7a86237-ece4-7cc4-e053-6294a90a1308 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:beb24a4f-ab0b-435a-b60b-2b8d565ecd75 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aabc64fe-1f17-4140-81f2-7d4506db6c8b (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db5f7ee5-9bd9-1819-e053-2a95a90a91df (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c638ab70-05dd-4f8b-9a11-b33a75f8c504 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
.6 (7.5 to 23.1) 1.10 (0.51 to 2.22) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52b8be5c-ef88-dfa7-e063-6394a90a0500 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9a4309e-fe43-4a26-a30f-c6577d650336 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cf33586-e48a-4b4e-b14b-33de2be63c1d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b0f0209-edbd-46f3-9bed-762cbea0d737 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
gine 17 2.0 (0.75-5.93) 12.6 (7.5-23.1) 1.21 (0.66-1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e849033b-a3bc-408e-88de-7cd1d2660949 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:634dbe6c-4874-4d54-aa25-be02d3341f16 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
2 (0.75 to 5.93) 12.6 (7.5 to 23.1) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:545fcc0e-1e2b-bdcb-e063-6294a90a4ac7 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3448839b-4933-4ef9-a80a-9e504d2c5696 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
.6 (7.5 to 23.1) 1.10 (0.51 to 2.22) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:380bddae-5b31-4965-96de-97711d859d11 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
gine 17 2.0 12.6 1.21 (0.75-5.93) (7.5-23.1) (0.66-1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d7c2d52-a78e-4508-8853-ba306cdeeaba (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
.6 (7.5 to 23.1) 1.10 (0.51 to 2.22) 1.21 (0.66 to 1.82) Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6139a858-700c-4eb9-9f84-99d280bde326 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Absorption Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%).
21%
- Numeric value
- 21
- Unit
- %
- Source records
- 16
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 16 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bd7193f-a81a-4909-90c2-7f324fc6ddfd (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb436371-d188-4803-a864-07b90c357e57 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faee013c-cad2-4abb-904c-e6ff79ba778c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e2c9a35-6a39-41d7-ad84-3c0bb8894b09 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:260dc37d-6e64-4688-82dc-10a1a428af17 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36f383af-8b71-4875-85ef-3a7a8b1d8805 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52df02a7-83da-4b20-9951-69790237dc24 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0833d3df-2df1-4abd-abe0-7fb2c0253c80 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87beaf22-593d-4170-bb58-332c615ef90d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffa46cb2-16e7-45f3-9940-5cb88d0cda9d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a69542ea-5b6f-15c1-9e7a-90ac839971d3 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ab07d6b-ae4a-a310-5572-b266676cd29e (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de7f61ca-e3c0-4a09-b664-0df2de6a0c30 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa679e97-3b3d-4bf2-8de7-da3a89e38b37 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5ec4d58-c669-4ab4-ba62-b71007536854 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a63e19c0-a093-e896-e053-2a95a90a7ccd (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs.
Projected row 818
- Medicine slug
- lamotrigine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 102
- Source count
- 99
- Agreement rate
- 1
- Recorded readings
31.2 hours
- Numeric value
- 31.2
- Unit
- hours
- Source records
- 99
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 99 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bd7193f-a81a-4909-90c2-7f324fc6ddfd (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de700ac1-4048-467e-abb1-238953261a97 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1a0da17-d67c-e44f-bd42-33c4009e4cdd (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf03f130-067f-401c-8501-0d78a989a319 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bbc140c-6092-416d-865d-49b89c5ecdd0 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dfdcc2d-b7c5-7abf-e063-6394a90a24a6 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.4 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e1e4fa8-881c-4618-88f6-018ab15db44d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb436371-d188-4803-a864-07b90c357e57 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47fd2592-2fc6-9787-e063-6394a90a8f01 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e5c2d76-47a6-4a57-b23c-2398b307380c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12e0be85-0961-4fe0-b973-83251ecf0f65 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20e156df-a2b6-4710-b526-0419cd17dd33 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f41c7e-03a6-b84c-e063-6294a90a7d82 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1691a60-ff0a-4755-b445-1d78309d5af0 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e243e803-e95f-47a6-a6da-5fed657f4462 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:811188be-d231-4b58-8d7a-b01b236fab51 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:812bc0d8-bb31-4fb1-9f4a-f8c17cbc769c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44670496-41ea-36a1-c435-32e359766a74 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faee013c-cad2-4abb-904c-e6ff79ba778c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83297e2e-9199-4b3d-9f44-a921787758fe (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 hours to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 mL/min/kg to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f31e1854-6068-4e45-b1e5-6def862fc466 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68a4dac2-5015-40c5-88ca-204098c3b288 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ef17301-6c0b-4941-a84d-12243875d2e2 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.4 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e2c9a35-6a39-41d7-ad84-3c0bb8894b09 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36f383af-8b71-4875-85ef-3a7a8b1d8805 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52273d60-3f27-4846-bf40-014ebcf09417 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:474fb321-575c-4b97-9dbe-080061652ee4 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:346f8af3-b850-48e4-bd6e-82ecafca86d2 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35aa48a2-2ce6-4a6e-bf5a-1bc6111d1234 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f7e59d2-4311-42a0-93a0-b29b0417d96f (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e6cc1ad-55cd-4c7f-878c-fa6716e95897 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dfb5f87-0150-4c26-a89f-34f1ab389500 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 hours to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 mL/min/kg to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7587283-781b-e111-e053-6394a90ad4cc (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f54690b3-bcbb-4d94-95b9-b7591af00117 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:003663e5-c0c7-4fc1-a64d-313f2a5b10d2 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.4 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52df02a7-83da-4b20-9951-69790237dc24 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:022b0913-f683-4af8-a862-f81b315909b2 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15d801a0-f0a5-40c1-bc88-d5ba9a02c696 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e08920c2-04a3-4fb5-acc5-0af3140f82e9 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b94ae2e4-e276-40c1-bc25-da980194fc99 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03fd8413-df56-50ab-e063-6394a90a6950 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50fcf452-2d21-493e-a1dd-0c6ea9ac6184 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df34faa4-829e-413a-a230-cbec604eead9 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.4 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03610cdf-7eaa-445c-a441-ff17be5a7c68 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.4 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7977c87f-b459-486a-9edc-0a2071c46f4c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22225cc4-028e-43ad-8e1f-dcebdc244ecb (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60958229-5b5f-49e2-97f4-a8722138f7ce (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.4 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54ea1ec3-876b-4d3a-a92b-1a6d70951de0 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b829f9b2-f0ac-408a-a6f4-18b72150227d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05cba628-b12c-44d8-89a8-3522fe417cc1 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.4 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70cd448a-2921-4c69-bdf2-5a6ce883bd07 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d33c4293-347c-49a1-9d98-f291c3dab6da (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53774022-ea0c-42a9-a720-dc755c77b851 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09a0d30d-9b8f-4c76-8cdb-8492386b2254 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67cf961e-02b9-4a99-944f-43a55df6a544 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b72ea7a-a0b0-4980-84ad-84f64e2e6368 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5761818-4eaf-4335-a77a-9cd703278ded (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50d46278-636a-470e-afcc-d3c8bd844e46 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ccb33cd0-e5f7-4a50-8b55-ad7c432cdb77 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.4 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcdb94a8-33be-6375-98ef-6933999d157f (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ca9d713-ab63-48bf-9386-29301a842e60 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0833d3df-2df1-4abd-abe0-7fb2c0253c80 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a9575bb-230e-46ae-b58e-41554bad45eb (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16323699-9bf8-43c7-b3aa-589156377872 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57f04b9b-06cd-8044-e063-6394a90ae733 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 hours to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 mL/min/kg to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7e3572d-56fe-4727-2bb4-013ccca22678 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87beaf22-593d-4170-bb58-332c615ef90d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ac9dc83-edb2-4ae5-8064-40f113fd3aab (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffa46cb2-16e7-45f3-9940-5cb88d0cda9d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:065e97c9-3c5f-16e6-e063-6294a90a13fc (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84277e2c-370c-4510-92bc-ef33a4a0f508 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc6e6735-d49a-44d8-936d-7c33437bc59e (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6034a8b8-9e80-43ca-b84f-ea82f788268c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ad18b68-ba16-4810-9c3e-27fa970454e8 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1601109-5c17-4482-9257-1e0be7546e8f (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ed4590d-71e3-4208-b6c0-98330acc7b85 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b5646a9-4724-44b8-8cd0-9c14f5e87f86 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a835b697-2beb-1ba8-e053-2995a90a470c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bbbe2a2-a9e8-8c13-e063-6394a90a9627 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7a86237-ece4-7cc4-e053-6294a90a1308 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:beb24a4f-ab0b-435a-b60b-2b8d565ecd75 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aabc64fe-1f17-4140-81f2-7d4506db6c8b (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db5f7ee5-9bd9-1819-e053-2a95a90a91df (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c638ab70-05dd-4f8b-9a11-b33a75f8c504 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52b8be5c-ef88-dfa7-e063-6394a90a0500 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9a4309e-fe43-4a26-a30f-c6577d650336 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.4 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de7f61ca-e3c0-4a09-b664-0df2de6a0c30 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa679e97-3b3d-4bf2-8de7-da3a89e38b37 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cf33586-e48a-4b4e-b14b-33de2be63c1d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b0f0209-edbd-46f3-9bed-762cbea0d737 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e849033b-a3bc-408e-88de-7cd1d2660949 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:634dbe6c-4874-4d54-aa25-be02d3341f16 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5ec4d58-c669-4ab4-ba62-b71007536854 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:545fcc0e-1e2b-bdcb-e063-6294a90a4ac7 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3448839b-4933-4ef9-a80a-9e504d2c5696 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:380bddae-5b31-4965-96de-97711d859d11 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d7c2d52-a78e-4508-8853-ba306cdeeaba (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6139a858-700c-4eb9-9f84-99d280bde326 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a63e19c0-a093-e896-e053-2a95a90a7ccd (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).
Projected row 819
- Medicine slug
- lamotrigine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 102
- Source count
- 102
- Agreement rate
- 1
- Recorded readings
55%
- Numeric value
- 55
- Unit
- %
- Source records
- 102
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 102 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bd7193f-a81a-4909-90c2-7f324fc6ddfd (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de700ac1-4048-467e-abb1-238953261a97 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1a0da17-d67c-e44f-bd42-33c4009e4cdd (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf03f130-067f-401c-8501-0d78a989a319 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bbc140c-6092-416d-865d-49b89c5ecdd0 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dfdcc2d-b7c5-7abf-e063-6394a90a24a6 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e1e4fa8-881c-4618-88f6-018ab15db44d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb436371-d188-4803-a864-07b90c357e57 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47fd2592-2fc6-9787-e063-6394a90a8f01 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding: Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e5c2d76-47a6-4a57-b23c-2398b307380c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 mcg/mL to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12e0be85-0961-4fe0-b973-83251ecf0f65 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20e156df-a2b6-4710-b526-0419cd17dd33 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Vd/F is independent of dose and is similar following single and multiple doses in both patients with epilepsy and in healthy volunteers Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f41c7e-03a6-b84c-e063-6294a90a7d82 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1691a60-ff0a-4755-b445-1d78309d5af0 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e243e803-e95f-47a6-a6da-5fed657f4462 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:811188be-d231-4b58-8d7a-b01b236fab51 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:812bc0d8-bb31-4fb1-9f4a-f8c17cbc769c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44670496-41ea-36a1-c435-32e359766a74 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faee013c-cad2-4abb-904c-e6ff79ba778c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83297e2e-9199-4b3d-9f44-a921787758fe (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 mcg/mL to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f31e1854-6068-4e45-b1e5-6def862fc466 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68a4dac2-5015-40c5-88ca-204098c3b288 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding: Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ef17301-6c0b-4941-a84d-12243875d2e2 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e2c9a35-6a39-41d7-ad84-3c0bb8894b09 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:260dc37d-6e64-4688-82dc-10a1a428af17 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36f383af-8b71-4875-85ef-3a7a8b1d8805 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52273d60-3f27-4846-bf40-014ebcf09417 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:474fb321-575c-4b97-9dbe-080061652ee4 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:346f8af3-b850-48e4-bd6e-82ecafca86d2 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35aa48a2-2ce6-4a6e-bf5a-1bc6111d1234 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f7e59d2-4311-42a0-93a0-b29b0417d96f (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e6cc1ad-55cd-4c7f-878c-fa6716e95897 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dfb5f87-0150-4c26-a89f-34f1ab389500 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 mcg/mL to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7587283-781b-e111-e053-6394a90ad4cc (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f54690b3-bcbb-4d94-95b9-b7591af00117 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:003663e5-c0c7-4fc1-a64d-313f2a5b10d2 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52df02a7-83da-4b20-9951-69790237dc24 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:022b0913-f683-4af8-a862-f81b315909b2 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15d801a0-f0a5-40c1-bc88-d5ba9a02c696 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e08920c2-04a3-4fb5-acc5-0af3140f82e9 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b94ae2e4-e276-40c1-bc25-da980194fc99 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding: Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03fd8413-df56-50ab-e063-6394a90a6950 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50fcf452-2d21-493e-a1dd-0c6ea9ac6184 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df34faa4-829e-413a-a230-cbec604eead9 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03610cdf-7eaa-445c-a441-ff17be5a7c68 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7977c87f-b459-486a-9edc-0a2071c46f4c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22225cc4-028e-43ad-8e1f-dcebdc244ecb (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60958229-5b5f-49e2-97f4-a8722138f7ce (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54ea1ec3-876b-4d3a-a92b-1a6d70951de0 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b829f9b2-f0ac-408a-a6f4-18b72150227d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding: Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05cba628-b12c-44d8-89a8-3522fe417cc1 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70cd448a-2921-4c69-bdf2-5a6ce883bd07 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d33c4293-347c-49a1-9d98-f291c3dab6da (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53774022-ea0c-42a9-a720-dc755c77b851 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09a0d30d-9b8f-4c76-8cdb-8492386b2254 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67cf961e-02b9-4a99-944f-43a55df6a544 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b72ea7a-a0b0-4980-84ad-84f64e2e6368 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5761818-4eaf-4335-a77a-9cd703278ded (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50d46278-636a-470e-afcc-d3c8bd844e46 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ccb33cd0-e5f7-4a50-8b55-ad7c432cdb77 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcdb94a8-33be-6375-98ef-6933999d157f (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ca9d713-ab63-48bf-9386-29301a842e60 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0833d3df-2df1-4abd-abe0-7fb2c0253c80 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a9575bb-230e-46ae-b58e-41554bad45eb (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16323699-9bf8-43c7-b3aa-589156377872 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57f04b9b-06cd-8044-e063-6394a90ae733 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 mcg/mL to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7e3572d-56fe-4727-2bb4-013ccca22678 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87beaf22-593d-4170-bb58-332c615ef90d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ac9dc83-edb2-4ae5-8064-40f113fd3aab (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffa46cb2-16e7-45f3-9940-5cb88d0cda9d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:065e97c9-3c5f-16e6-e063-6294a90a13fc (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84277e2c-370c-4510-92bc-ef33a4a0f508 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc6e6735-d49a-44d8-936d-7c33437bc59e (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a69542ea-5b6f-15c1-9e7a-90ac839971d3 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6034a8b8-9e80-43ca-b84f-ea82f788268c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ad18b68-ba16-4810-9c3e-27fa970454e8 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1601109-5c17-4482-9257-1e0be7546e8f (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ed4590d-71e3-4208-b6c0-98330acc7b85 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b5646a9-4724-44b8-8cd0-9c14f5e87f86 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ab07d6b-ae4a-a310-5572-b266676cd29e (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a835b697-2beb-1ba8-e053-2995a90a470c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bbbe2a2-a9e8-8c13-e063-6394a90a9627 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7a86237-ece4-7cc4-e053-6294a90a1308 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:beb24a4f-ab0b-435a-b60b-2b8d565ecd75 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aabc64fe-1f17-4140-81f2-7d4506db6c8b (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db5f7ee5-9bd9-1819-e053-2a95a90a91df (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c638ab70-05dd-4f8b-9a11-b33a75f8c504 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52b8be5c-ef88-dfa7-e063-6394a90a0500 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9a4309e-fe43-4a26-a30f-c6577d650336 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de7f61ca-e3c0-4a09-b664-0df2de6a0c30 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa679e97-3b3d-4bf2-8de7-da3a89e38b37 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cf33586-e48a-4b4e-b14b-33de2be63c1d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b0f0209-edbd-46f3-9bed-762cbea0d737 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e849033b-a3bc-408e-88de-7cd1d2660949 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:634dbe6c-4874-4d54-aa25-be02d3341f16 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5ec4d58-c669-4ab4-ba62-b71007536854 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:545fcc0e-1e2b-bdcb-e063-6294a90a4ac7 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3448839b-4933-4ef9-a80a-9e504d2c5696 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:380bddae-5b31-4965-96de-97711d859d11 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d7c2d52-a78e-4508-8853-ba306cdeeaba (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6139a858-700c-4eb9-9f84-99d280bde326 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a63e19c0-a093-e896-e053-2a95a90a7ccd (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
Protein Binding Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials).
Projected row 820
- Medicine slug
- lamotrigine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 102
- Source count
- 16
- Agreement rate
- 1
- Recorded readings
4 to 6 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 16
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 16 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bd7193f-a81a-4909-90c2-7f324fc6ddfd (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release tablets was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb436371-d188-4803-a864-07b90c357e57 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faee013c-cad2-4abb-904c-e6ff79ba778c (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release tablets was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e2c9a35-6a39-41d7-ad84-3c0bb8894b09 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of LAMICTAL XR was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:260dc37d-6e64-4688-82dc-10a1a428af17 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release tablets was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36f383af-8b71-4875-85ef-3a7a8b1d8805 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release tablets was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52df02a7-83da-4b20-9951-69790237dc24 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release tablets was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0833d3df-2df1-4abd-abe0-7fb2c0253c80 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87beaf22-593d-4170-bb58-332c615ef90d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release tablets was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffa46cb2-16e7-45f3-9940-5cb88d0cda9d (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release tablets was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a69542ea-5b6f-15c1-9e7a-90ac839971d3 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release tablets was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ab07d6b-ae4a-a310-5572-b266676cd29e (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release tablets was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de7f61ca-e3c0-4a09-b664-0df2de6a0c30 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release tablets was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa679e97-3b3d-4bf2-8de7-da3a89e38b37 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5ec4d58-c669-4ab4-ba62-b71007536854 (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release tablets was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a63e19c0-a093-e896-e053-2a95a90a7ccd (opens source in a new tab)
Lamotrigine label
Version not recorded · Effective date not recorded
In this study, the median time to peak concentration (T max ) following administration of lamotrigine extended-release was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=810Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.